ArticleEndocrine, metabolic & immune disorders drug targets2026
The Impact of Selenium Deficiency and Supplementation on Hashimoto's Thyroiditis: A Clinical Evaluation.
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHashimoto thyroiditis (HT) is an autoimmune disorder that leads to hypothyroidism. Selenium (Se) is essential for thyroid hormone metabolism and immune function, but its role in HT remains debated. This study investigates Se levels in HT patients and evaluates the impact of supplementation on thyroid autoimmunity and thyroid function.
methodsThis retrospective study analyzed HT patients and healthy controls. Biochemical parameters, including Se, thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4), anti-thyroid peroxidase (anti-TPO), and anti-thyroglobulin (anti-Tg) antibodies, were compared. Se-deficient HT patients (<80 μg/L) received selenium supplementation for six months. Paired t-tests and Spearman correlation analyses were used for statistical evaluation.
resultsAmong 270 HT patients and 350 controls, TSH levels were significantly elevated in HT (p<0.001), whereas Se levels showed no significant baseline difference (p=0.87). In Se-deficient patients (n=60), supplementation increased Se levels from 68.60 ± 12.10 μg/L to 104.92 ± 34.45 μg/L (p<0.001). However, anti-TPO and anti-Tg levels increased after treatment (p=0.01 and p=0.03, respectively). No significant changes were observed in TSH (p=0.27), FT3 (p=0.20), or FT4 (p=0.19). Se positively correlated with anti-TPO (r=0.36, p=0.0102) and negatively with FT3 (r=-0.39, p=0.0046). DISCUSSION: Selenium supplementation restored serum Se levels but was unexpectedly associated with increased antibody titers. This finding contrasts with several randomized trials reporting antibody reduction, suggesting that baseline Se status, the form of supplementation, or differences in study design may account for the discrepancy. The observed correlations should be interpreted with caution.
conclusionSelenium supplementation normalizes selenium status in HT patients, but its effects on thyroid autoimmunity and thyroid function remain uncertain. Long-term randomized controlled trials are needed to determine its therapeutic value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.